Trial Profile
A Phase 1, Dose-Rising Study of AMD11070 in HIV-Seronegative Men to Assess the Safety and Pharmacokinetics After Single or Multiple Doses
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 May 2012
Price :
$35
*
At a glance
- Drugs Mavorixafor (Primary) ; Ritonavir
- Indications HIV infections; HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- 06 Apr 2012 Actual patient number 44 added as reported by ClinicalTrials.gov.
- 26 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Oct 2006 Status change